OptiLight is an intense pulsed light (IPL) device designed for a consistent, precise, and controlled light-based treatment of signs of dry eye disease due to meibomian gland dysfunction.
Lumenis’ multi-centre, double-blinded, randomised controlled trial showed that Lumenis IPL with patented Optimal Pulse Technology (OPT) significantly improved tear break-up time, meibum quality, and meibomian gland expressibility.1 The clinical trial joins a long list of studies of Lumenis’ IPL with OPT that have shown the same results, as well as reduction of inflammatory markers.2-5
Contact: Lumenis (AUS) 1800 586 364 or (NZ) 0800 239 015
References
1. FDA study sponsored by Lumenis: internal reference LUM-VBU-M22-IPL-17-01.
2. Yan, X., et al., The efficacy of intense pulsed light combined with meibomian gland expression for the treatment of dry eye disease due to meibomian gland dysfunction: A multicenter, randomized controlled trial. Eye Contact Lens. 2021 Jan 1;47(1):45–53. doi: 10.1097/ICL.0000000000000711. PMID: 32452923; PMCID: PMC7752242.
3. Arita, R., et al., Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocul Surf. 2019 Jan;17(1):104–110. doi: 10.1016/j.jtos.2018.11.004. Epub 2018 Nov 13. PMID: 30445177.
4. Gao, Y.F., et al., Comparison of anti-inflammatory effects of intense pulsed light with tobramycin/dexamethasone plus warm compress on dry eye associated meibomian gland dysfunction. Int J Ophthalmol. 2019 Nov 18;12(11):1708–1713. doi: 10.18240/ijo.2019.11.07. PMID: 31741858; PMCID: PMC6848864.
5. Liu, R., et al., Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. Am J Ophthalmol. 2017 Nov;183:81–90. doi: 10.1016/j.ajo.2017.08.021. Epub 2017 Sep 6. PMID: 28887117.
